MedTrace Logo

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 206

Last updated 2026-01-09

No results posted yet for this study

Summary

Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

Conditions

  • Conventional Chondrosarcoma

Interventions

DRUG

INBRX-109

Tetravalent DR5 Agonist Antibody

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Inhibrx Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Clinical Lead · Inhibrx Biosciences, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-23
Primary Completion
2025-09-30
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • France
  • Germany
  • Ireland
  • Italy
  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04950075 on ClinicalTrials.gov